Passage Bio Inc (PASG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$5.14+5.98%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Passage Bio is cutting costs by cutting 75% of its workers. Operating losses improved from -$13.85M to -$8.25M in one quarter. The company extended its cash runway to the first quarter of 2027. It completed an acquisition to boost its pipeline.
The company still loses a lot of money and burns cash. Earnings estimates are falling, showing no profit soon. It cut many partnerships and had costly lease terminations.
The stock trades about 38% below our fair value near $8. The market expects continued losses and no revenue growth soon.
Breaks if: Cash runway does not extend through 2027-Q1
Breaks if: No meaningful clinical progress or partnership management
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is navigating through a merger and clinical development while facing high risks and volatility in management performance.
The market appears to have low expectations for PASG, as indicated by its neutral recent financial performance and low fragility tier. Investors may not be anticipating significant positive changes in the near term.
Fundamentals are likely to remain under pressure due to ongoing losses and the need for significant operational restructuring. The recent workforce reduction shows some progress in cost management, but overall performance remains mixed.
The thesis hinges on the successful integration of the merger with Remix Therapeutics and advancements in clinical trials for PBFT02. Additionally, broader sector performance and economic conditions will play a crucial role in shaping outcomes.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Workforce reduction falls short of 75% by Q3 2026
Implement workforce reduction of approximately 75% to decrease operating expenses and complete restructuring by Q3 2026.
Stated in 1 quarter (2026-Q2). The company announced a workforce reduction of approximately 75% to reduce operating expenses, with implementation expected to complete by Q3 2026. Operating income improved from -$13.8M in 2025-Q4 to -$8.3M in 2026-Q2, indicating some progress. The trajectory shows initial delivery on cost reduction efforts.
“Announced workforce reduction of approximately 75% to decrease operating expenses.”
Breaks if: Failure to complete acquisitions or control restructuring costs
Oversee strategic review, corporate restructuring, and related M&A activities to maximize shareholder value.
Newly stated in 2026-Q2. Management announced a strategic review process including potential M&A and restructuring activities to maximize shareholder value. This is an ongoing priority with no direct financial metrics disclosed yet. The trajectory is early stage with active management focus.
“Company has initiated a review of strategic alternatives to maximize shareholder value.”
Over the next 1 to 3 years, PASG faces significant challenges that could impact its growth trajectory. Not investment advice.